Older Americans' risk-benefit preferences for modifying the course of alzheimer disease

A. Brett Hauber, F. Reed Johnson, Howard Fillit, Ateesha F. Mohamed, Christopher Leibman, Michael Arrighi, Michael Grundman, Raymond J. Townsend

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Alzheimer disease (AD) is a progressive, ultimately fatal neurodegenerative illness affecting millions of patients, families, and caregivers. Effective disease-modifying therapies for AD are desperately needed, but none currently exist on the market. Thus, accelerating the discovery, development, and approval of new disease-modifying drugs for AD is a high priority for individuals, physicians, and medical decision makers. Potentially disease-modifying drugs likely will have significant therapeutic benefits but also may have treatment-related risks. We quantified older Americans' treatment-related risk tolerance by eliciting their willingness to accept the risk of treatment-related death or permanent severe disability in exchange for modifying the course of AD. A stated-choice survey instrument was administered to 2146 American residents 60 years of age and older. On average, subjects were willing to accept a 1-year risk of treatment-related death or permanent severe disability from stroke of over 30% for a treatment that prevents AD from progressing beyond the mild stage. Thus, most people in this age cohort are willing to accept considerable risks in return for disease-modifying benefits of new AD drugs. These results are consistent with other studies indicating that individuals view AD as a serious, life threatening illness that imposes heavy burdens on both patients and caregivers.

Original languageEnglish
Pages (from-to)23-32
Number of pages10
JournalAlzheimer Disease and Associated Disorders
Volume23
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Keywords

  • Alzheimer disease
  • Benefit
  • Preferences
  • Risk
  • Treatment

Fingerprint

Dive into the research topics of 'Older Americans' risk-benefit preferences for modifying the course of alzheimer disease'. Together they form a unique fingerprint.

Cite this